BeiGene Ltd. (NASDAQ: BGNE) saw its shares pop early on Thursday after the firm announced that it had entered into a strategic collaboration with Celgene Corp. (NASDAQ: CELG). The goal is to commercialize Beigene’s investigational anti-programmed cell death protein 1 (PD-1) inhibitor, BGB-A317, for patients with solid tumor cancers in the United States, Europe, Japan and rest of world outside Asia.